Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a...

Area of Science:

• Hematology
• Pharmacology
• Medical Devices

Background:

• Adherence to hydroxyurea (HU) is critical for managing sickle cell vaso-occlusive pain.
• Identifying barriers to medication adherence is essential for improving patient outcomes.

Purpose of the Study:

• To evaluate the effectiveness of an electronic medication monitoring device (GlowCap™) in tracking hydroxyurea adherence.
• To determine if the GlowCap™ device impacts hydroxyurea adherence rates in sickle cell patients.

Main Methods:

• A study involving a questionnaire and an electronic medication container-monitor-reminder device (GlowCap™).
• Nineteen subjects participated in the survey, and 17 in the intervention phase, with 12 providing reliable adherence data.
• Adherence was tracked using the GlowCap™ device and medication possession ratio.

Main Results:

• The most common barriers to adherence were lack of reminders and absence of home medicine delivery.
• The median adherence rate for patients using the GlowCap™ was 85%.
• The GlowCap™ device accurately recorded adherence and may be an effective tool for improving medication adherence.

Conclusions:

• The GlowCap™ electronic monitoring device shows potential for enhancing hydroxyurea adherence in sickle cell patients.
• Addressing barriers like reminders and delivery services is important for improving medication adherence.
• This technology offers a reliable method for tracking adherence and supporting patient self-management.